<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9349">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02985229</url>
  </required_header>
  <id_info>
    <org_study_id>1028</org_study_id>
    <nct_id>NCT02985229</nct_id>
  </id_info>
  <brief_title>Acceptability and Feasibility of Medical Abortion in Singapore</brief_title>
  <official_title>Acceptability and Feasibility of Medical Abortion in Singapore: A Study of 800 μg Buccal Misoprostol Following 200 mg Mifepristone for Abortion Through 70 Days Gestation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynuity Health Projects</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gynuity Health Projects</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To test the hypothesis that a regimen of 200 mg oral mifepristone, with the option of home
      administration, followed by 800 μg buccal misoprostol 24 hours later for abortion through 70
      days LMP will be feasible and acceptable in Singapore.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of successful abortion</measure>
    <time_frame>One Month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Whether women prefer to take mifepristone in the clinic or at home</measure>
    <time_frame>One Month</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Medical Abortion</condition>
  <arm_group>
    <arm_group_label>All participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants in the study will be given the option of home administration of 200 mg oral mifepristone and 800 μg buccal misoprostol for medical abortion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mifepristone</intervention_name>
    <description>The option of home or clinic administration of 200 mg oral mifepristone</description>
    <arm_group_label>All participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <description>800 μg buccal misoprostol through 70 days LMP following administration of mifepristone</description>
    <arm_group_label>All participants</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have an intrauterine pregnancy consistent wit gestational age ≤ 70 days

          -  Be 21 years of age or over

          -  Be willing and able to sign consent forms

          -  Be eligible for abortion according to current hospital guidelines

          -  Be able to return to the clinic and able to contact study staff or emergency medical
             services if needed

          -  Be willing to provide an address, email and/or telephone number for purposes of
             follow-up

          -  Agree to comply with the study procedures and visit schedule

        Exclusion Criteria:

          -  confirmed or suspected ectopic pregnancy or undiagnosed adnexal mass

          -  chronic renal failure

          -  concurrent long-term corticosteroid therapy

          -  history of inherited porphyrias

          -  IUD in place (must be removed after mifepristone is administered).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beverly Winikoff, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gynuity Health Projects</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yi-Ling Tan, MPH</last_name>
    <phone>2124481230</phone>
    <phone_ext>222</phone_ext>
    <email>ytan@gynuity.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>KK Women's and Children's Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Koh, MD</last_name>
    </contact>
    <investigator>
      <last_name>Kok Hian Tan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arundhati Kosavi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Kuldip Singh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 8, 2016</lastchanged_date>
  <firstreceived_date>October 19, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mifepristone</mesh_term>
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
